Abstract
CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus. The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL). Eight hundred twenty-one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, resp...Continue Reading
References
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Jun 14, 2006·Cancer·Philippe E SpiessLouis L Pisters
Jan 18, 2007·The Oncologist·Edwin P RockRichard Pazdur
Jul 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David CellaWilliam P Bro
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toni K ChoueiriMario Sznol
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Paul G KluetzSandra A Mitchell
Jun 11, 2016·The Lancet Oncology·David CellaRobert J Motzer
Oct 11, 2016·Journal of Cancer Research and Therapeutics·Ming GuoJingfeng Zhang
Mar 1, 2018·The Oncologist·Nizar M TannirMichael B Atkins
Aug 21, 2019·The Lancet Oncology·Robert J MotzerUNKNOWN CheckMate 214 investigators
Sep 11, 2019·The Oncologist·Jad ChahoudNizar M Tannir
Mar 13, 2020·The Oncologist·Jad ChahoudNizar M Tannir
Citations
Oct 4, 2020·Cancers·Wei LiuAleksandra A Pandyra
Nov 12, 2020·Cancers·Linda QuatriniLorenzo Moretta
Nov 15, 2020·Urologic Oncology·Jad ChahoudNizar M Tannir
Jan 26, 2021·Frontiers in Genetics·Ergang GuoGuoqing Hu
Nov 10, 2020·IJU Case Reports·Takashi Kobayashi
Jan 12, 2021·Journal for Immunotherapy of Cancer·Marion AlloucheryUNKNOWN French Network of Regional Pharmacovigilance Centers
Jan 9, 2021·Frontiers in Oncology·Matthew D TuckerBrian I Rini
Mar 25, 2021·Journal of Translational Medicine·Andrea BotticelliPaolo Marchetti
Mar 24, 2021·Acta Clinica Belgica·Michael SaerensWillem Lybaert
Apr 2, 2021·OncoTargets and Therapy·Yan ZhengFengmin Shao
Apr 13, 2021·Cancer Letters·Baohua LuoChanghong Shi
Mar 13, 2021·International Journal of Cancer. Journal International Du Cancer·Nizar M TannirAung Naing
Jun 9, 2021·Proceedings of the National Academy of Sciences of the United States of America·Yuping ZhangArul M Chinnaiyan
May 18, 2021·Frontiers in Oncology·Dharmesh GopalakrishnanSaby George
May 29, 2021·Therapeutic Advances in Medical Oncology·Sara Elena RebuzziGiuseppe Fornarini
Jun 8, 2021·Urologic Oncology·Daniel M GeynismanEric A Singer
Jun 13, 2021·Urologic Oncology·Alexander S Taylor, Stephanie L Skala
Jun 15, 2021·Frontiers in Oncology·Jiexuan HuBangwei Cao
Jun 17, 2021·Current Problems in Cancer·Deniz Can GuvenSaadettin Kilickap
Jul 15, 2021·Journal of Medical Economics·Hansoo KimDanny Liew
Jul 23, 2021·Expert Review of Anticancer Therapy·Lothar BergmannMarit Ahrens
Jul 25, 2021·Cancers·Veronica MollicaAndrea Ardizzoni
Jul 25, 2021·Journal for Immunotherapy of Cancer·Aung NaingAlexander Spira
Aug 5, 2021·Journal of Translational Medicine·Marco StellatoDaniele Santini
Aug 19, 2021·Cancer Medicine·Tressie HerrmannHakim Mahammedi
Aug 19, 2021·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN KEYNOTE-564 Investigators
Jul 5, 2021·ESMO Open·I ReschM Schmidinger
Sep 3, 2021·Journal of Cancer Research and Clinical Oncology·Rui MaoDong Zhou
Sep 11, 2021·Frontiers in Immunology·Lin Zhou, Xin Wei
Oct 3, 2021·Journal for Immunotherapy of Cancer·Alice TzengMoshe C Ornstein
Nov 3, 2021·Future Oncology·Emre YekedüzYüksel Ürün